MXPA04006650A - Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo. - Google Patents
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo.Info
- Publication number
- MXPA04006650A MXPA04006650A MXPA04006650A MXPA04006650A MXPA04006650A MX PA04006650 A MXPA04006650 A MX PA04006650A MX PA04006650 A MXPA04006650 A MX PA04006650A MX PA04006650 A MXPA04006650 A MX PA04006650A MX PA04006650 A MXPA04006650 A MX PA04006650A
- Authority
- MX
- Mexico
- Prior art keywords
- transfer protein
- cholesteryl ester
- pharmaceutical compositions
- ester transfer
- solid amorphous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Una composicion farmaceutica comprende una dispersion amorfa solida de un inhibidor de la proteina de transferencia de esteres de colesterilo y un polimero que aumenta la concentracion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/066,091 US7235259B2 (en) | 2000-08-03 | 2002-02-01 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
PCT/IB2003/000310 WO2003063832A1 (en) | 2002-02-01 | 2003-01-28 | Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04006650A true MXPA04006650A (es) | 2004-10-04 |
Family
ID=27658640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04006650A MXPA04006650A (es) | 2002-02-01 | 2003-01-28 | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo. |
Country Status (14)
Country | Link |
---|---|
US (1) | US7235259B2 (es) |
EP (2) | EP2305217B1 (es) |
JP (1) | JP2005523895A (es) |
AR (1) | AR038375A1 (es) |
BR (1) | BR0307277A (es) |
CA (1) | CA2474447A1 (es) |
GT (1) | GT200300021A (es) |
MX (1) | MXPA04006650A (es) |
PA (1) | PA8564901A1 (es) |
PE (1) | PE20040187A1 (es) |
SV (1) | SV2004001473A (es) |
TW (1) | TW200307565A (es) |
UY (1) | UY27639A1 (es) |
WO (1) | WO2003063832A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9712544B1 (pt) | 1996-10-18 | 2013-10-22 | Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos | |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
CN1309370C (zh) | 2002-02-01 | 2007-04-11 | 辉瑞产品公司 | 使用改进的喷雾干燥设备制备均匀喷雾干燥的固体非晶形药物分散体的方法 |
EP1474144B1 (en) | 2002-02-01 | 2008-08-06 | Pfizer Products Inc. | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
EP1578415B1 (en) | 2002-12-20 | 2008-09-10 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
ZA200508159B (en) * | 2003-03-17 | 2007-03-28 | Japan Tobacco Inc | Pharmaceutical compositions of CETP inhibitors |
US20040225018A1 (en) * | 2003-03-17 | 2004-11-11 | Japan Tobacco Inc. | Pharmaceutical compositions of CETP inhibitors |
CL2004001884A1 (es) * | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
TWI359147B (en) | 2003-09-05 | 2012-03-01 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv n |
NZ546677A (en) * | 2003-11-14 | 2008-11-28 | Pfizer Prod Inc | Solid amorphous dispersions of an MTP inhibitor for treatment of obesity |
JP2007513143A (ja) * | 2003-12-04 | 2007-05-24 | ファイザー・プロダクツ・インク | 押出機を使用して好ましくはポロクサマーおよびグリセリドを含む多粒子アジスロマイシン組成物を製造するための噴霧凝固法 |
BRPI0417348A (pt) * | 2003-12-04 | 2007-03-13 | Pfizer Prod Inc | processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo |
CA2569310A1 (en) * | 2004-06-08 | 2005-12-29 | Maura Murphy | Pharmaceutical compositions |
WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
EP1848430B1 (en) | 2004-12-31 | 2017-08-02 | Dr. Reddy's Laboratories Ltd. | Novel benzylamine derivatives as cetp inhibitors |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
BRPI0620960A2 (pt) | 2005-12-28 | 2011-11-29 | Vertex Pharmaceuticals Incorporated | formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-didro-4- oxiquinolina-3- carboxamida |
US8039475B2 (en) | 2006-02-27 | 2011-10-18 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
JP2009531315A (ja) | 2006-03-16 | 2009-09-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | 重水素化c型肝炎プロテアーゼインヒビター |
CN101494979A (zh) * | 2006-03-20 | 2009-07-29 | 沃泰克斯药物股份有限公司 | 药物组合物 |
KR20090115970A (ko) | 2007-02-27 | 2009-11-10 | 버텍스 파마슈티칼스 인코포레이티드 | 공-결정 및 그를 포함하는 제약 조성물 |
CA2679426A1 (en) | 2007-02-27 | 2008-09-04 | Luc Farmer | Inhibitors of serine proteases |
US20100119612A1 (en) * | 2007-04-17 | 2010-05-13 | Bend Research, Inc | Nanoparticles comprising non-crystalline drug |
NZ583699A (en) | 2007-08-30 | 2012-04-27 | Vertex Pharma | Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same |
CN101820863A (zh) * | 2007-10-10 | 2010-09-01 | 马林克罗特贝克公司 | 直接可压制的高功能性颗粒状微晶纤维素基赋形剂、其制备方法和用途 |
US20100055180A1 (en) * | 2007-10-10 | 2010-03-04 | Mallinckrodt Baker, Inc. | Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof |
MX2011013080A (es) | 2009-06-16 | 2012-01-20 | Pfizer | Formas de dosis de apixaban. |
JP2014505714A (ja) | 2011-02-17 | 2014-03-06 | エフ.ホフマン−ラ ロシュ アーゲー | ホットメルト押出法による過冷却液体状態からの活性医薬成分の制御された結晶化方法 |
CA2828610A1 (en) | 2011-03-08 | 2012-09-13 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
EP2744803A2 (en) | 2011-08-18 | 2014-06-25 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors |
EP2760864B1 (en) | 2011-09-27 | 2018-01-24 | Dr. Reddy's Laboratories Ltd. | 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS |
KR20150084873A (ko) * | 2012-11-19 | 2015-07-22 | 닥터 레디스 레보러터리즈 리미티드 | Cetp 억제제의 약학적 조성물 |
IN2014DE01467A (es) | 2013-06-03 | 2015-07-24 | Shinetsu Chemical Co | |
US20180282527A1 (en) | 2017-03-30 | 2018-10-04 | Shin-Etsu Chemical Co., Ltd. | Injection molding composition containing hypromellose acetate succinate and method for producing same |
CA3221313A1 (en) * | 2021-06-09 | 2022-12-15 | Warren Miller | Mixed solvents for spray drying for preparation of amorphous solid dispersions |
DE102021003906B4 (de) | 2021-07-30 | 2023-03-30 | Mirco Bienhaus | Verfahren und Vorrichtungen zur Herstellung fester oder halbfester Arzneiformen mit einem mehrschichtigen Aufbau |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
DE3612212A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
EP0299641B1 (en) | 1987-07-17 | 1992-06-10 | Dow Corning Corporation | A curable composition |
JP2528706B2 (ja) | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
DK0580860T4 (da) * | 1991-04-16 | 2005-03-21 | Nippon Shinyaku Co Ltd | Fremgangsmåde til fremstilling af en fast dispersion |
US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
DE4316537A1 (de) | 1993-05-18 | 1994-11-24 | Basf Ag | Zubereitungen in Form fester Lösungen |
WO1996015141A1 (en) | 1994-11-12 | 1996-05-23 | Lg Chemical Ltd. | Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents |
DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
GB2305665A (en) | 1995-09-26 | 1997-04-16 | Merck & Co Inc | Selective ß3 agonists for the treatment of diabetes aand obesity |
DE19610932A1 (de) | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
EP0801060A1 (en) | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
JPH10287662A (ja) | 1997-04-08 | 1998-10-27 | Kitasato Inst:The | Fo−5637a物質及びb物質並びにそれらの製造法 |
DK0901786T3 (da) * | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
WO1999014204A1 (en) * | 1997-09-16 | 1999-03-25 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
MA24643A1 (fr) | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
DE19741399A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
AU3285499A (en) | 1998-02-13 | 1999-08-30 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6140342A (en) | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
WO2000018721A1 (en) | 1998-09-25 | 2000-04-06 | Monsanto Company | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
WO2000018723A1 (en) | 1998-09-25 | 2000-04-06 | Monsanto Company | Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
DE60039379D1 (de) * | 1999-02-10 | 2008-08-21 | Pfizer Prod Inc | Pharmazeutische feste Dispersionen |
CN1139660C (zh) | 1999-03-08 | 2004-02-25 | 社团法人北里研究所 | Wk-5344a物质和wk-5344b物质及其生产 |
US6465011B2 (en) | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US20010018446A1 (en) | 1999-09-23 | 2001-08-30 | G.D. Searle & Co. | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
US20010028895A1 (en) | 2000-02-04 | 2001-10-11 | Bisgaier Charles L. | Methods of treating alzheimer's disease |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
CZ20033457A3 (cs) | 2001-06-22 | 2004-09-15 | Pfizer Products Inc. | Farmaceutická kompozice zahrnující léčiva s nízkou rozpustností a/nebo léčiva citlivá na kyselinu a neutralizované kyselé polymery |
JP2004534812A (ja) | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | 薬物および中性ポリマーの分散物の医薬組成物 |
-
2002
- 2002-01-30 AR ARP030100274A patent/AR038375A1/es unknown
- 2002-02-01 US US10/066,091 patent/US7235259B2/en not_active Expired - Fee Related
-
2003
- 2003-01-27 TW TW092101730A patent/TW200307565A/zh unknown
- 2003-01-28 WO PCT/IB2003/000310 patent/WO2003063832A1/en active Application Filing
- 2003-01-28 BR BR0307277-0A patent/BR0307277A/pt not_active IP Right Cessation
- 2003-01-28 EP EP10181825.0A patent/EP2305217B1/en not_active Expired - Lifetime
- 2003-01-28 JP JP2003563526A patent/JP2005523895A/ja active Pending
- 2003-01-28 CA CA002474447A patent/CA2474447A1/en not_active Abandoned
- 2003-01-28 EP EP20030700432 patent/EP1469831A1/en not_active Withdrawn
- 2003-01-28 MX MXPA04006650A patent/MXPA04006650A/es unknown
- 2003-01-30 GT GT200300021A patent/GT200300021A/es unknown
- 2003-01-30 PE PE2003000109A patent/PE20040187A1/es not_active Application Discontinuation
- 2003-01-31 SV SV2003001473A patent/SV2004001473A/es not_active Application Discontinuation
- 2003-01-31 UY UY27639A patent/UY27639A1/es not_active Application Discontinuation
- 2003-02-03 PA PA20038564901A patent/PA8564901A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2003063832A1 (en) | 2003-08-07 |
US7235259B2 (en) | 2007-06-26 |
JP2005523895A (ja) | 2005-08-11 |
GT200300021A (es) | 2003-09-04 |
PE20040187A1 (es) | 2004-03-20 |
EP1469831A1 (en) | 2004-10-27 |
AR038375A1 (es) | 2005-01-12 |
SV2004001473A (es) | 2004-05-07 |
UY27639A1 (es) | 2003-09-30 |
BR0307277A (pt) | 2004-10-26 |
PA8564901A1 (es) | 2003-11-12 |
EP2305217B1 (en) | 2014-07-30 |
CA2474447A1 (en) | 2003-08-07 |
EP2305217A1 (en) | 2011-04-06 |
TW200307565A (en) | 2003-12-16 |
US20030186952A1 (en) | 2003-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04006650A (es) | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo. | |
AP2001002235A0 (en) | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors. | |
TW200517145A (en) | Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | |
AU2002243402A1 (en) | Inhibitors of histone deacetylase | |
AU2482800A (en) | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors | |
AU2003221786A1 (en) | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | |
AU2003278795A1 (en) | Compositions containing oil silicon-polyamide polymer and short chain ester | |
AU2003237121A1 (en) | Pyrrole derivatives as inhibitors of erk2 and uses thereof | |
TW200420301A (en) | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | |
AP2002002621A0 (en) | Pharmaceutical compositions of glycogen phosphorylase inhibitors | |
AU2003285677A1 (en) | Compositions of cholesteryl ester transfer protein inhibitors and hmg-coa reductase inhibitors | |
AU2003211093A1 (en) | Inhibitors of rgs proteins | |
AU2003249309A1 (en) | Stents capable of controllably releasing histone deacetylase inhibitors | |
AU2003247390A1 (en) | Histone deacetylase inhibitors based on alphachalcogenmethylcarbonyl compounds | |
AU2003269421A1 (en) | Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use | |
AU2003243285A1 (en) | Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds | |
AU2001233837A1 (en) | Benzthiazoles as tnf and pde-iv inhibitors | |
AU2001245764A1 (en) | Novel compounds and compositions as protease inhibitors | |
AU2003243272A1 (en) | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | |
AU2003291567A1 (en) | Polymeric boronic acid derivatives as lipase inhibitors | |
AU2003285755A1 (en) | Low-voltage discharge lamp and backlight device using same | |
AU2003237983A1 (en) | Derivatives of azepine and thiazeran as interleukin converting enzyme inhibitors | |
AU2003269027A1 (en) | Novel pharmaceutical compositions based on 5-alpha-reductase inhibitors and uses of same | |
AU2003277878A1 (en) | Arylsulfonylhydroxamic acid and amide derivatives and their use as protease inhibitors | |
AU2003215130A1 (en) | Composition and method for modulating an inflammatory response |